Menu Back toSpeakers

DIA Annual Canadian Meeting

Transformation with Collaboration


  • Lisa  Chartrand

    Lisa Chartrand

    • Director, Regulatory Affairs and Quality Management
    • Hoffmann-La Roche Limited, Canada

    Lisa Chartrand began her 20 year career in the industry with Apotex as a quality assurance chemist and found her passion in Regulatory Affairs when she joined EMD Serono in 1999. At Roche Canada since 2003, she has enjoyed many growth opportunities in Regulatory Affairs and Medical Affairs and was appointed Director, Regulatory Affairs and Quality Management in 2014. Lisa is an active member of both Innovative Medicines Canada's Regulatory Affairs Committee and of BioteCanada's Biologics Regulatory Affairs Group (BRAG). Lisa earned her Bachelors of Science in Microbiology and Immunology from McGill University in Montreal, Quebec and holds a certificate from the Toronto Institute of Pharmaceutical Technology in Quality Assurance.

  • Loretta  Del Bosco

    Loretta Del Bosco

    • Director, Regulatory Affairs Quality Assurance Operations
    • AbbVie Corporation, Canada

    Loretta has spent several decades in the Canadian pharmaceutical industry and is the current Director, Regulatory Affairs, Quality Assurance and Operations, AbbVie Canada, the Vice-Chair of Canada’s Innovative Medicines Canada Regulatory Affairs Committee and member of BIOTECanada’s Subsequent Entry Biologics Committee and Biologics Regulatory Affairs Group. A member of the McGill University Faculty of Science Advisory Board and Microbiology and Immunology McGill graduate.

  • Karen  Feltmate

    Karen Feltmate

    • President
    • Redstone Health Group, Inc., Canada

    Karen Feltmate is the President of Redstone Health Group Inc., a consulting firm providing regulatory strategy and guidance to the innovative Pharmaceutical industry. Karen has over 20 years of corporate executive experience primarily in the area of Canadian Federal registration and also manufacturing, packaging, quality and distribution. Karen holds a B.Sc. in Biology from McMaster University. She is a past Board member of both the Canadian Pharmaceutical Distribution Network (CPDN) and the University of Toronto Biotechnology Bridging Program. She is a member of the Drug Information Association, and was a founding member of the Canadian Association of Professionals in Regulatory Affairs (CAPRA).

  • Fiona  Frappier, PhD

    Fiona Frappier, PhD

    • Senior Policy Analyst
    • Health Canada, Canada

  • Melissa  Hunt, MSc

    Melissa Hunt, MSc

    • Scientific Manager
    • Health Canada, Canada

    Melissa Hunt joined Health Canada in 2005. She holds a Bachelor of Science in Life Sciences from Queen’s University and a Master of Science in Pharmacology from the University of Toronto. Prior to working at Health Canada, Melissa worked for several years within the pharmaceutical industry in pharmacovigilance. Melissa has worked as both a Scientific Evaluator and, in her current position, a Manager in the Marketed Pharmaceuticals and Medical Devices Bureau (MPMDB) of the Marketed Health Products Directorate (MHPD) at Health Canada; where she has been responsible for the evaluation and management of a number of drug safety issues.

  • Keith  McIntosh

    Keith McIntosh

    • Executive Director, Scientific & Regulatory Affairs
    • Innovative Medicines Canada, Canada

    Keith McIntosh is Executive Director, Scientific & Regulatory Affairs at Innovative Medicines Canada, and joined the organization in 2012. Previously, Keith spent 12 years in progressively senior policy and regulatory roles at another trade association. He has successfully advocated industry positions to federal, provincial and municipal departments and agencies covering a diversity of issues and topics. Keith has primary responsibility for the association’s interactions with Health Canada’s drug review bureaus, and developing the association’s positions on regulatory proposals and amendments. He also supports the work of the Regulatory Affairs and PMPRB committees, among others.

  • Rania  Mouchantaf, PhD

    Rania Mouchantaf, PhD

    • Proactive Pharmacovigilance-Risk Management Planning
    • Health Canada, Canada

    Dr. Mouchantaf over 10 years of experience in the area of pharmacovigilance and drug safety. In addition to her role as manager, Dr. Mouchantaf chairs the Risk Management Plan Working group where she has lead the standardization of the risk management planning review process both internally and externally to Health Canada. Before entering the government Dr. Mouchantaf worked in the area of business development at Paladin labs in Montreal. Her education includes a Bachelor degree in Microbiology and Immunology and a doctorate degree in Pharmacology and Therapeutics, both of which are from McGill university. She also completed a post-doctoral fellowship at the university of Montreal in the area of oncology and breast cancer research.

  • Lissa  Murseli

    Lissa Murseli

    • Manager
    • Health Canada, Canada

    Lissa Murseli is a manager at Health Canada's Health Products and Food Branch, within the Policy, Planning and International Affairs Directorate. Prior to this, Lissa was a senior advisor to Health Canada’s Deputy Minister, where she helped to coordinate a range of regulatory and policy files. Lissa's previous experience includes regulatory and operational roles within the office of Health Canada that regulates tobacco products. Lissa completed a Master of Public Health and Bachelor of Science at the University of British Columbia.

  • Polina  Ostrovsky, MPH

    Polina Ostrovsky, MPH

    • Policy Analyst
    • Health Canada, Canada

  • Marc F. Poitras, PhD, MBA

    Marc F. Poitras, PhD, MBA

    • Scientific Manager, Marketed Pharmaceuticals and Medical Devices Bureau
    • Health Canada, Canada

    Dr. Poitras has worked at Health Canada in different capacities in Pharmacovigilance and drug safety for the last 9 years. His undergraduate and graduate training includes a BSc in Biotechnology and MSc/PhD degrees in Pharmacology from the University of Sherbrooke. He also completed post-doctoral training programs in cellular biology and neuroscience at Johns Hopkins University and New York University. He then completed a MBA at the University of Ottawa. Dr. Poitras is currently working as a Scientific Manager at the Marketed Health Products Directorate.

  • Kristin  Willemsen, MS

    Kristin Willemsen, MS

    • Director of Scientific & Regulatory Affairs
    • Consumer Health Products Canada, Canada

    Kristin Willemsen is the Director of Scientific and Regulatory Affairs at Consumer Health Products Canada. For ten years, she has been working with members to influence guidance, policy and regulation of Over-the-counter Drugs and Natural Health Products. Kristin has a Masters of Science from the University of Ottawa and she is a Certified Association Executive.

  • Ashley  Zakhem

    Ashley Zakhem

    • Policy Analyst
    • Health Canada, Canada

    Ashley Zakhem is a Policy Analyst at Health Canada who works on strategic horizontal policy files related to health products and food including: healthy eating strategy, marketing to kids and financial transparency.

  • Megan  Bettle, PhD

    Megan Bettle, PhD

    • Director, Regulatory Review of Drugs and Devices
    • Health Canada, Canada

    Megan Bettle has a PhD from the Department of Pathology at Queen’s University, followed by post-doctoral work on the genetics of a rare developmental disease, and on developing novel molecules for treatment of hemophilia. She joined Health Canada in 2005 as a drug safety reviewer. Since then, she has developed broader regulatory experience across the department, working in the areas of pre- and post-market drug regulation, developing the rules for the first commercial medical marijuana program, and conducting surveillance of tobacco and illicit drug use. She is currently the director of the Regulatory Review of Drugs and Devices (R2D2) initiative, a multi-year project aimed at improving access to medicines for Canadian patients.

  • Léo  Bouthillier, PhD

    Léo Bouthillier, PhD

    • Director, Bureau of Cardiology, Allergy and Neurological Sciences
    • Health Canada, Canada

  • Robert  Ghiz

    Robert Ghiz

    • President and CEO
    • Canadian Wireless Telecommunications Association, Canada

  • David K. Lee

    David K. Lee

    • Chief Regulatory Officer for Health Product and Food Branch
    • Health Canada, Canada

    David K. Lee is the Chief Regulatory Officer for the Health Products and Food Branch, Health Canada.He was previously the Director of the Office of Legislative and Regulatory Modernization. In this capacity, he led modernization initiatives for the Food and Drugs Act and Regulations. Prior to that he was the Director of the Office of Patented Medicines and Liaison. David received his law degree at Queen’s University and articled at the Federal Court of Canada. He has lectured extensively on intellectual property law and food and drug law both nationally and internationally.

  • Sarah  Lussier Hoskyn, MA

    Sarah Lussier Hoskyn, MA

    • Senior Analyst, Regulatory Affairs and Market Access
    • Innovative Medicines Canada, Canada

  • Yola  Moride, PhD, FISPE

    Yola Moride, PhD, FISPE

    • Professor, Faculty of Pharmacy
    • University of Montreal, Canada

    Yola Moride has received degrees in genetics and pharmacoepidemiology from McGill University, as well as pharmacovigilance from the University of Bordeaux in France. Dr. Moride has over 15 years of experience in the conduct of drug safety and utilization studies. She holds university and hospital

  • Pierre  Sabourin, MBA

    Pierre Sabourin, MBA

    • Assistant Deputy Minister, Health Products and Food Branch
    • Health Canada, Canada

    Pierre Sabourin was appointed Assistant Deputy Minister (ADM) of the Health Products and Food Branch at Health Canada in 2016. He was the Senior Vice-President at Canada Mortgage and Housing Corporation (CMHC) from 2013 – 2014. From 2010 to 2013, he held the position of Vice-President, Operations at Canada Border Services Agency where he led all Canadian customs and immigration border operations.

  • Meredith Y. Smith, PhD, MPA

    Meredith Y. Smith, PhD, MPA

    • Global Risk Management Officer, Global Patient Safety
    • Amgen Inc., United States

    Meredith Smith is Global Risk Management Officer, Global Patient Safety & Labeling at Amgen, Inc. where she leads a team of scientists responsible for medicinal product benefit-risk assessment and risk management. Trained as a health services researcher, Dr. Smith has over 15 years of experience in the pharmaceutical industry in the areas of benefit-risk assessment, health outcomes and health economics, health policy, risk management, clinical research and development, drug safety, and patient-focused drug development. She has been an invited member of numerous FDA expert panels on benefit-risk management-related topics and has published widely in the peer-reviewed literature.

  • Rachel E. Sobel, DrPH, MPH, FISPE

    Rachel E. Sobel, DrPH, MPH, FISPE

    • Senior Director, Epidemiology - Group Lead
    • Pfizer Inc, United States

    Dr. Sobel is a Group Lead, Epidemiology, Worldwide Safety and Regulatory group at Pfizer. In her >18 year career, her responsibilities have included general epidemiology support and contributing to the design, implementation, and evaluation of risk management strategies for medicines in a number of therapeutic areas.